Revance Therapeutics reported $92.47M in Operating Expenses for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 10036M 518M
Adamas Pharmaceuticals ADMS:US 31.53M 405K
Aerie Pharmaceuticals AERI:US $ 61.69M 3M
ALKERMES ALKS:US 313.8M 14.5M
Biodelivery Sciences International BDSI:US $ 25.47M 4.6M
Bristol Myers Squibb BMY:US $ 9.63B 360M
Cara Therapeutics CARA:US $ 21.4M 9.48M
Coherus Biosciences CHRS:US $ 115.29M 3.48M
Eli Lilly And LLY:US $ 5296.8M 39.9M
Endo International Ordinary Shares ENDP:US $ 682.87M 112.15M
Flexion Therapeutics FLXN:US $ 44.98M 73K
Gw Pharmaceuticals GWPH:US 173.49M 2.46M
Horizon Pharma HZNP:US $ 705.45M 11.42M
JAZZ PHA JAZZ:US $ 809.75M 11.66M
Johnson & Johnson JNJ:US $ 19.49B 2.84B
Merk MRK:US $ 8328M 1460M
Neurocrine Biosciences NBIX:US $ 251.5M 25.4M
Pacira Pharmaceuticals PCRX:US $ 96.29M 4.46M
Procter & Gamble PG:US $ 15315M 91M
Revance Therapeutics RVNC:US $ 92.47M 3.33M
Supernus Pharmaceuticals SUPN:US $ 115.86M 8.64M
Teva Pharmaceutical Industries TEVA:US 3.26B 64M
Zogenix ZGNX:US $ 76.48M 2.26M